Replies to post #220496 on Biotech Values

[DewDiligence]

IMDX -43% on phase-2 failure of CMB305 and other stuff:

https://finance.yahoo.com/news/immune-design-announces-program-updates-200100046.html

Based on a recent review of the CMB305 program, including an early analysis of the ongoing Phase 2 study that showed the combination of CMB305 and Tecentriq (atezolizumab) is not likely to show a survival benefit in relapsed synovial sarcoma patients, the company has decided to discontinue the SYNOVATE trial. Immune Design will seek external collaborations to explore the continued development of CMB305 in sarcoma.